research use only

Pimonidazole

Name: Pimonidazole
Brand: Selleck Chemicals
SKU: S9919
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9919

Pimonidazole (Ro 03-8799) is a novel hypoxia marker used for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma.

Chemical Structure

Molecular Weight: 254.29

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: S991901 DMSO]51 mg/mL]false]Ethanol]51 mg/mL]false]Water]Insoluble]false Purity: 99.52%

99.52

Related Targets	Dyes Antineoplastic and Immunosuppressive Antibiotics ADC Cytotoxin Selection Antibiotics for Transfected Cell PROTAC Antibiotics for Mammalian Cell Culture ADC Linker Antibiotics for Plant Cell Culture PROTAC Linker Hydrotropic Agents Antibody-Drug Conjugate E3 ligase Ligand Target Protein Ligand Molecular Glues Enzyme Substrate Drug-Linker Conjugates for ADC Chelating Agent
Related Products	BAPTA-AM Rat IgG2b isotype control-InVivo Blebbistatin Methyl-β-cyclodextrin (MβCD) AP-III-a4 (ENOblock) Carbazochrome sodium sulfonate (AC-17) Ursolic Acid Osthole 4-Methylumbelliferone (4-MU) Dioscin Ethidium bromide Pitstop 2 Sesamin Bilobalide Formononetin Hesperidin Azeliragon (TTP488) L-Mimosine Carbenoxolone Sodium Vitexin N6022 Dp44mT Chlorogenic Acid Sphingosine Chrysin Coenzyme Q10 (CoQ10) Spermine Tetrahydrochloride 2-NBDG D-Lin-MC3-DMA (MC3) Morin Hydrate

Chemical Information, Storage & Stability

Molecular Weight	254.29	Formula	C₁₁H₁₈N₄O₃	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	70132-50-2	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Ro 03-8799			Smiles	OC(CN1CCCCC1)C[N]2C=CN=C2[N+]([O-])=O

Solubility

In vitro
Batch:

DMSO : 51 mg/mL ( (200.55 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 51 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

In vitro	Pimonidazole has radio-sensitivity and recovery capacity from radiation-induced damage depend on p53 status of the tumor cell.<sup><a class="sref" href="#s_ref">[3]</a></sup>
In vivo	Pimonidazole can overcome radiation resistance in hypoxiaby melanoma cells, which is enhanced by liposome modification.<sup><a class="sref" href="#s_ref">[2]</a></sup>
References	https://pubmed.ncbi.nlm.nih.gov/9826471/ https://pubmed.ncbi.nlm.nih.gov/27580239/ https://pubmed.ncbi.nlm.nih.gov/22905487/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03718650	Withdrawn	Pancreatic Cancer\|Resectable Pancreatic Cancer	H. Lee Moffitt Cancer Center and Research Institute\|Varian Medical Systems	April 1 2021	Early Phase 1
NCT03410420	Suspended	Aortic Aneurysm Thoracic	University of Maryland Baltimore	October 1 2018	Phase 1
NCT03262311	Completed	Cancer	Institute of Cancer Research United Kingdom	November 10 2017	Not Applicable
NCT02624115	Completed	Colon Rectal Cancer Adenocarcinoma	University Health Network Toronto	May 1 2016	--
NCT02095249	Active not recruiting	Prostate Cancer	University Health Network Toronto	September 2014	Not Applicable
NCT00374517	Withdrawn	Refractory Pulmonary Tuberculosis	National Institute of Allergy and Infectious Diseases (NIAID)\|International Tuberculosis Research Center\|National Institutes of Health Clinical Center (CC)	September 5 2006	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):